The Roles of sPLA2s in Skin Homeostasis and Disease

Biomolecules. 2023 Apr 12;13(4):668. doi: 10.3390/biom13040668.

Abstract

Among the phospholipase A2 (PLA2) family, the secreted PLA2 (sPLA2) family in mammals contains 11 members that exhibit unique tissue or cellular distributions and enzymatic properties. Current studies using knockout and/or transgenic mice for a nearly full set of sPLA2s, in combination with comprehensive lipidomics, have revealed the diverse pathophysiological roles of sPLA2s in various biological events. Individual sPLA2s exert specific functions within tissue microenvironments, likely through the hydrolysis of extracellular phospholipids. Lipids are an essential biological component for skin homeostasis, and disturbance of lipid metabolism by deletion or overexpression of lipid-metabolizing enzymes or lipid-sensing receptors often leads to skin abnormalities that are easily visible on the outside. Over the past decades, our studies using knockout and transgenic mice for various sPLA2s have uncovered several new aspects of these enzymes as modulators of skin homeostasis and disease. This article summarizes the roles of several sPLA2s in skin pathophysiology, providing additional insight into the research fields of sPLA2s, lipids, and skin biology.

Keywords: contact hypersensitivity; dendritic cell; epidermis; gut microbiota; hair follicle; keratinocyte; lipid metabolism; phospholipase A2; psoriasis; skin.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Homeostasis
  • Mammals / metabolism
  • Mice
  • Mice, Transgenic
  • Phospholipases A2, Secretory* / genetics
  • Phospholipases A2, Secretory* / metabolism
  • Phospholipids / metabolism
  • Skin / metabolism

Substances

  • Phospholipases A2, Secretory
  • Phospholipids

Grants and funding

This work was supported by Grants-in-Aid for Scientific Research JP19H03372 (to K.Y.) and JP20H05691 (to M.M.) from Japan Society for the Promotion and Science, and PRIME JP18gm5910012 (to K.Y.) and AMED-CREST JP22gm1210013 (to M.M.) from the Japan Agency for Medical Research and Development.